COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE

• US 20100056572A1
• Filed: 07/09/2007
• Published: 03/04/2010
• Est. Priority Date: 07/10/2006
• Status: Active Grant

• Current Assignee: Synapsin Pharmaceuticals Inc.
• Original Assignee: Synapsin Pharmaceuticals Inc.
• Inventors: Dorsey, Denis, Kindy, Mark S.
• Granted Patent: US 8,524,741 B2
• Time in Patent Office: Days
• US Class Current: 514/315
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Provided herein are piperidine alkaloids and uses thereof in neurological disorders and physical enhancement applications.

Claims

1. A method of treating or preventing neurodegenerative disease in a subject comprising identifying a subject at risk for neurodegenerative disease and administering to the subject a therapeutically effective amount of a composition comprising a piperidine alkaloid.

2. The method of claim 1, wherein the composition comprises an extract of fire ant (Solenopsis invicta) venom.

3. The method of claim 1, wherein the piperidine alkaloid comprises the formula

wherein R¹ is a substituted or unsubstituted aliphatic group having from 7 to 30 carbon atoms.

4. The method of claim 1, wherein the piperidine alkaloid comprises 2-methyl-6-alkyl-piperidine.

5. The method of claim 1, wherein the piperidine alkaloid is Solenopsin A.

6. The method of claim 1, wherein the piperidine alkaloid is selected from the group consisting of cis-2-methyl-6-undecylpiperidine, trans-2-methyl-6-undecylpiperidine, cis-2-methyl-6-tridecylpiperidine, trans-2-methyl-6-tridecylpiperidine, cis-2-methyl-6-pentadecylpiperidine, trans-2-methyl-6-pentadecylpiperidine, cis-2-methyl-6-(cis-4-tridecen-1-yl)piperidine, trans-2-methyl-6-(cis-4-tridecen-1-yl)piperidine, cis-2-methyl-6-(cis-4-pentadecen-1-yl)piperidine, trans-2-methyl-6-(cis-4-pentadecen-1-yl)piperidine.

7. The method of claim 1, wherein the piperidine alkaloid is 2-methyl-6-undecylpiperidine.

8. The method of claim 1, wherein the subject has been diagnosed with Alzheimer'"'"'s disease.

9. The method of claim 1, wherein the composition is administered to the subject orally, systemically, or intracranially.

10. A method of treating a subject at risk for Alzheimer'"'"'s disease comprising administering to the subject a composition comprising a piperidine alkaloid.

11. A method of enhance the physical performance in a subject by administering to the subject a composition comprising a piperidine alkaloid.